Catalogue


Networks of innovation [electronic resource] : vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 /
Louis Galambos with Jane Eliot Sewell.
imprint
Cambridge ; New York : Cambridge University Press, 1995.
description
xi, 273 p., [4] p. of plates : ill. (some col.), ports.
ISBN
0521563089 (hardback), 9780521563086 (hardback)
format(s)
Book
More Details
added author
imprint
Cambridge ; New York : Cambridge University Press, 1995.
isbn
0521563089 (hardback)
9780521563086 (hardback)
restrictions
Licensed for access by U. of T. users.
catalogue key
8367918
 
Includes bibliographical references snd index.
A Look Inside
Reviews
Review Quotes
"Networks of Innovation deserves a careful and thoughtful reading by historians of technology because it shows how it is possible to analyze effectively the role of individuals in the process of technological change without losing the insights and rigor that come from sociological and economic theory." W. Bernard Carlson, Technology and Culture
"...best described by its subtitile because of the narrow focus on the chronological history of Merck's vaccine unit." Book Reviews
"Galambos and Sewell's well-documented book is a valuable and unusual contribution to the history of specialized pharmaceutical endeavor in America, with emphasis on the networking required on the long road leading to each new vaccine." Glenn Sonnedecker, American Historical Review
'The work is admirably referenced and will be of value to all who take an interest in the field of biologicals. It will repay careful reading by those involved in the management of innovation in the pharmaceutical industry.' John Hunt, The Pharmaceutical Journal
'The work is admirably referenced and will be of value to all who take an interest in the field of biologicals. It will repay careful reading by those involved in the management of innovation in the pharmaceutical industry.'John Hunt, The Pharmaceutical Journal
‘The work is admirably referenced and will be of value to all who take an interest in the field of biologicals. It will repay careful reading by those involved in the management of innovation in the pharmaceutical industry.’John Hunt, The Pharmaceutical Journal
"...this is a most impressive work....superb at showing the requisites for successful vaccine innovation. It provides outside observers rare insight into decision making processes at a leading pharmaceutical firm." Marvin Fischbaum, H-Net Reviews
"It is beautifully written." Journal of Interdisciplinary History
"Rigorously researched and crisply written, Networks of Innovation....makes a strong case for science-based firms' building and sustaining organizational capabilities to achieve technological innovation as well as to accomodate shifting competitive and regulatory environments." David B. Sicilia, The Journal of American History
To find out how to look for other reviews, please see our guides to finding book reviews in the Sciences or Social Sciences and Humanities.
Summaries
Description for Bookstore
Networks of Innovation offers an historical perspective on how private sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines, and how their activities were related to complex, evolving networks of scientific, governmental, and medical institutions.
Description for Library
Networks of Innovation offers an historical perspective on the manner in which private sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and upon Merck & Co., Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad.
Main Description
Networks of Innovation offers a historical perspective on the manner in which private sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and on Merck & Co., Inc., which merged with Sharp & Dohme in 1953. By surveying a century of innovation in biologicals, the authors show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad.
Main Description
Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals.
Table of Contents
Preface
1894: 'The foremost medical question of the day'
The Mulford story
A Sharp & Dohme interlude
The virology network and a new programme at Merck, Sharp & Dohme
Hilleman's innovations: first phase, measles-mumps-rubella
Dangerous interlude, Marek's Disease adjuvant 65, the Swine Flu drama
Transforming bacteriology: a second phase, meningitis, pneumonia, haemophilus, influenzae
New networks, new leadership: the Hepatitis B vaccines
Vaccine innovation in the nineties: new strategies, new structures, and public confrontations
A word about sources
Table of Contents provided by Publisher. All Rights Reserved.

This information is provided by a service that aggregates data from review sources and other sources that are often consulted by libraries, and readers. The University does not edit this information and merely includes it as a convenience for users. It does not warrant that reviews are accurate. As with any review users should approach reviews critically and where deemed necessary should consult multiple review sources. Any concerns or questions about particular reviews should be directed to the reviewer and/or publisher.

  link to old catalogue

Report a problem